Cardiac Marker, INR Testing are Major Focus of Point of Care Diagnostics

Posted on Updated on


The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016.

Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology and INR testing.

Healthcare expenditures of each country are mounting and nations are leaving no stone unturned in providing the best and advanced medical facilities to its populace. The prevalence of chronic and infectious diseases among the millennials has intensified and given rise to the need for better diagnostic methods. The point of care diagnostics (POC) has come to the rescue by proving its convenience in immediate testing and diagnosis of diseases. The popularity of these devices has contributed to a flourishing market. The major factor pushing ahead the POC diagnostics industry is the rise in health awareness spread by government entities.

The increase in the number of heart disorders and trauma injuries across the world are in need of diagnostic devices that can aid in prognosis. The clinically unmet need for cardiac testing devices as well as those medical devices that can monitor blood clotting are giving a real push to the point of care diagnostics industry. Both the categories are significant consumers of the market, and their demand is augmenting the growth of the market. According to the healthcare industy analyst firm Allied Market Research, the global POC diagnostics market is set to reach a market value of $43,336 million by 2022. This is a testimony to the immense potential possessed by the industry in diagnostics.

Cardiac POC Devices Ensure Better Heart Health

An alarming statistic revealed by the American Heart Association states that cardiac diseases account for close to 17.3 million death per year. The figure points towards the clinically unmet needs for timely diagnosis of craniological disorders. Essentially, the cardiac point-of-care testing in hospitals and homes as well leads to a better administering of patient care, by replacing centralized testing methods which are time-consuming. Cardiac bio-marker testing devices for monitoring the heart rate, inflammation threats, and potential heart failure can potentially avert complications and even cardiac arrests.

Read More:


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s